The influence of polyphenolic compounds and their metabolites on platelet activation by Applová, Lenka
Abstract 
 
Charles University, Faculty of Pharmacy in Hradec Králové 
Department of Pharmacology and Toxicology 
 
Candidate:    Applová Lenka, MSc. 
Supervisor:   Assoc. Prof. Přemysl Mladěnka, PharmD., Ph.D.  
Title of Doctoral Thesis: The influence of polyphenolic compounds and their metabolites on 
platelet activation 
 
Blood aggregation is a very difficult and complex process, in which platelets play crucial role. 
On the other hand, their activation is excessive and therefore undesirable under pathophysiological 
conditions. Cardiovascular diseases are the most common cause of mortality in developed countries 
and unfortunately, despite significant advances in treatment, the Czech Republic remains in mortality 
from these diseases behind most Western European countries. Epidemiological studies suggest, that 
higher intake of (iso)flavonoids is associated with reduced cardiovascular mortality. It is also worth 
mentioning, that the Czech Republic is among European countries with the lowest content of 
flavonoids in diet.  
The aim of this doctoral thesis was to find out, if polyphenolic compounds, especially 
(iso)flavonoids and/or their metabolites, are able to influence platelet aggregation and thus indirectly 
to support epidemiological findings, i.e. whether there may be a link between these substances and 
possible positive cardiovascular effect at experimental level. 
In summary, 16 isoflavonoids, 4 isoflavonoid metabolites, 29 flavonoid metabolites and  
12 synthetic xanthen-3-ones were tested in this thesis. At first, the screening was performed on 
aggregation induced by arachidonic acid (AA) and collagen with using of impedance aggregometry in 
whole human blood. In the case of very active substances, the mechanism of action was also tested: 
determination of cyclooxygenase-1 and thromboxane synthase inhibition, antagonism at 
thromboxane receptors, calcium signalling cascade interference or serotonin release inhibition. 
These experiments were performed principally by ELISA determination of final products or again by 
impedance aggregometry.  
First, the antiplatelet potential of isoflavonoids, which were the most effective flavonoids in 
previous studies, was tested. The good inhibitory effect of genistein and daidzein has been 
confirmed, but now also in whole human blood, i.e. under more clinically relevant biological 
conditions. Subsequently, these compounds inhibited platelet cyclooxygenase-1 and acted as 
antagonists at thromboxane receptors. Antagonism at these receptors has also been established as 
the major mechanism for the most potent compound, tectorigenin, whose IC50 values were three 
times lower than that of the standard, acetylsalicylic acid (ASA). Due to the poor bioavailability of 
parent compounds after oral administration due to their poor penetration into the gastrointestinal 
cells and/or their rapid metabolism in these cells, the proven isoflavonoid metabolites were tested. 
Of these, S-equol has shown the greatest effect that was similar to ASA on collagen induced 
aggregation. Another active metabolite was 4-ethylphenol, which was able to partially inhibit 
cyclooxygenase-1, antagonize thromboxane receptors and affect calcium homeostasis. The 
metabolite O-desmethylanolensin showed a lower effect, but shares the same mechanisms of action 
with 4-ethylphenol. In contrast, no antiplatelet effect was observed for (2RS)-2-(4-hydroxyphenyl) 
propionic acid.  
Based on pharmacokinetics of flavonoids and the fact, that these metabolites reach higher 
concentrations than parent flavonoids in plasma, these GIT metabolites were also tested. Only four 
compounds from 29 were able to inhibit platelet aggregation induced by AA;  
4-methylcatechol, pyrogallol, resorcinol and phloroglucinol. IC50 of 4-methylcatechol were 
approximately ten times lower than for ASA, both for aggregation induced by AA and by collagen. 
This compound was able to partially inhibit thromboxane synthase, but we assume that the main 
mechanism of action is based on influence on calcium kinetics. 4-methylcatechol and phloroglucinol 
are among other proven metabolites of the most commonly occurring flavonol quercetin. The effects 
of 4-methylcatechol and pyrogallol were also confirmed in a new in vivo (ex ovo) model of 
thrombosis. In this experiment, platelet aggregation was induced by local (topical) administration of 
AA. This resulted in 46 % mortality of the control samples after the first hour and 60 % after 24 hours. 
I.v. premedication with ASA reduced the mortality to 7 % and 27 %, respectively. Premedication with 
4-methylcatechol and pyrogallol was not associated with any mortality in the first hour. The 
corresponding values after 24 hours were 7 % and 31 %, respectively. 
A part of this thesis was also testing of the antiplatelet effects of newly synthesized 
compounds from the group of xanthene-3-one derivatives. From 12 tested substances, almost all 
were able to significantly inhibit AA induced platelet aggregation at a concentration of 80 µM. Only 
two compounds were active in lower concentrations and were subsequently tested more in depth. 9-
(2'-hydroxy-5'-bromophenyl)-2,6,7-trihydroxyxanthene-3-one inhibited ovine recombinant 
cyclooxygenase-1, but this effect was not confirmed in human platelet rich plasma. The second 
compound, (9-(4'-dimethylamino-phenyl)-2,6,7-trihydroxy-xanthen-3-one, was very active on 
collagen induced aggregation. In fact, its activity was even comparable with ASA. 
The mechanism of action was subsequently established as antagonism at thromboxane receptors.  
In conclusion, these published outcomes on polyphenolic substances, that form part of our diet and 
their gastrointestinal metabolites, suggest possible protective cardiovascular effects. However, for 
the most active substances there is still space for new information, especially their pharmacokinetics, 
and then their testing ex vivo and in vivo in combinations with clinically used antiplatelet agents. 
